Ryman Healthcare Limited (FRA:RH7)

Ryman Healthcare Statistics

Total Valuation

FRA:RH7 has a market cap or net worth of EUR 1.47 billion. The enterprise value is 2.30 billion.

Market Cap	1.47B
Enterprise Value	2.30B

Important Dates

The last earnings date was Thursday, November 27, 2025.

Earnings Date	Nov 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	1.01B
Shares Outstanding	n/a
Shares Change (YoY)	+27.13%
Shares Change (QoQ)	+38.62%
Owned by Insiders (%)	2.73%
Owned by Institutions (%)	48.02%
Float	987.03M

Valuation Ratios

PE Ratio	n/a
Forward PE	25.75
PS Ratio	3.69
PB Ratio	0.72
P/TBV Ratio	0.72
P/FCF Ratio	11.38
P/OCF Ratio	9.25
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 107.92, with an EV/FCF ratio of 17.82.

EV / Earnings	-8.27
EV / Sales	5.78
EV / EBITDA	107.92
EV / EBIT	n/a
EV / FCF	17.82

Financial Position

The company has a current ratio of 0.03, with a Debt / Equity ratio of 0.41.

Current Ratio	0.03
Quick Ratio	0.01
Debt / Equity	0.41
Debt / EBITDA	39.20
Debt / FCF	6.48
Interest Coverage	0.05

Financial Efficiency

Return on equity (ROE) is -13.37% and return on invested capital (ROIC) is 0.07%.

Return on Equity (ROE)	-13.37%
Return on Assets (ROA)	0.04%
Return on Invested Capital (ROIC)	0.07%
Return on Capital Employed (ROCE)	0.12%
Revenue Per Employee	51,829
Profits Per Employee	-36,202
Employee Count	7,700
Asset Turnover	0.06
Inventory Turnover	799.38

Taxes

In the past 12 months, FRA:RH7 has paid 68.89 million in taxes.

Income Tax	68.89M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -45.02% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-45.02%
50-Day Moving Average	1.33
200-Day Moving Average	1.29
Relative Strength Index (RSI)	59.64
Average Volume (20 Days)	1,321

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:RH7 had revenue of EUR 399.08 million and -278.76 million in losses. Loss per share was -0.32.

Revenue	399.08M
Gross Profit	26.13M
Operating Income	3.72M
Pretax Income	-209.87M
Net Income	-278.76M
EBITDA	19.47M
EBIT	3.72M
Loss Per Share	-0.32

Balance Sheet

The company has 4.63 million in cash and 838.46 million in debt, giving a net cash position of -833.84 million.

Cash & Cash Equivalents	4.63M
Total Debt	838.46M
Net Cash	-833.84M
Net Cash Per Share	n/a
Equity (Book Value)	2.04B
Book Value Per Share	2.01
Working Capital	-2.92B

Cash Flow

In the last 12 months, operating cash flow was 159.17 million and capital expenditures -29.82 million, giving a free cash flow of 129.35 million.

Operating Cash Flow	159.17M
Capital Expenditures	-29.82M
Free Cash Flow	129.35M
FCF Per Share	n/a

Margins

Gross margin is 6.55%, with operating and profit margins of 0.93% and -69.85%.

Gross Margin	6.55%
Operating Margin	0.93%
Pretax Margin	-52.59%
Profit Margin	-69.85%
EBITDA Margin	4.88%
EBIT Margin	0.93%
FCF Margin	32.41%

Dividends & Yields

FRA:RH7 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-27.13%
Shareholder Yield	-27.13%
Earnings Yield	-18.94%
FCF Yield	8.79%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:RH7 has an Altman Z-Score of -0.07 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.07
Piotroski F-Score	6